Source and scope
This summary is bounded to the recommendations, population and decisions covered by Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian anxiety CPG
Source-attributed clinical priorities
- Confirm the anxiety presentation while excluding urgent medical mimics, substance effects and co-occurring depression or suicide risk.
- Offer evidence-based psychological treatment and, when indicated, first-line pharmacotherapy chosen for the specific disorder and patient context.
- Avoid routine long-term benzodiazepine treatment; monitor response, function, adverse effects and relapse risk.
- Distinguish panic attacks occurring within another disorder from panic disorder and from cardiopulmonary or endocrine illness.
sources for this section:Canadian anxiety CPG
Practical assessment and management workflow
1
Map triggers, avoidance, anticipatory anxiety, physical symptoms and impairment across home, work and relationships.
2
Review caffeine, cannabis, stimulants, alcohol withdrawal, thyroid symptoms and medicines that can provoke anxiety.
3
Offer disorder-specific cognitive behavioural treatment and explain the expected early course of any medication trial.
4
Track avoidance and function as well as symptom scores, and build a relapse plan after sustained improvement.
sources for this section:Canadian anxiety CPG
Safety, red flags and urgent escalation
- Assess urgently when chest pain, syncope, severe dyspnea, intoxication or a new neurologic presentation suggests a medical emergency.
- Ask about suicide risk and severe depression even when anxiety is the presenting complaint.
- Warn that benzodiazepines impair driving, combine dangerously with opioids or alcohol and can cause dependence.
sources for this section:Canadian anxiety CPG
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian anxiety CPG
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian anxiety CPG
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Anxiety Disorders Association of CanadaCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.